Humacyte (NASDAQ:HUMA) Raised to Neutral at Piper Sandler
Piper Sandler upgraded shares of Humacyte (NASDAQ:HUMA – Free Report) from an underweight rating to a neutral rating in a research note issued to investors on Monday, Marketbeat reports. The brokerage currently has $3.50 price objective on the stock, up from their previous price objective of $2.75. Separately, Cantor Fitzgerald initiated coverage on Humacyte in […]